{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:05:33Z","timestamp":1752537933260,"version":"3.41.2"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"DOI":"10.1186\/s13075-025-03618-4","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T13:54:53Z","timestamp":1752501293000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Killing arthritogenic fibroblast-like synoviocytes: an example using cytotoxic aptamers binding nucleolin"],"prefix":"10.1186","volume":"27","author":[{"given":"George D.","family":"Kalliolias","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Efthimia K.","family":"Basdra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athanasios G.","family":"Papavassiliou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,14]]},"reference":[{"issue":"7","key":"3618_CR1","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1002\/art.41720","volume":"73","author":"H K\u00e4llmark","year":"2021","unstructured":"K\u00e4llmark H, Einarsson JT, Nilsson J\u00c5, et al. Sustained remission in patients with rheumatoid arthritis receiving triple therapy compared to biologic therapy: A Swedish nationwide register study. Arthritis Rheumatol. 2021;73(7):1135\u201344. https:\/\/doi.org\/10.1002\/art.41720.","journal-title":"Arthritis Rheumatol"},{"key":"3618_CR2","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S0140-6736(20)32341-2","volume":"397","author":"F Humby","year":"2021","unstructured":"Humby F, Durez P, Buch MH, et al. Rituximab versus Tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. Lancet. 2021;397:305\u201317. https:\/\/doi.org\/10.1016\/S0140-6736(20)32341-2.","journal-title":"Lancet"},{"key":"3618_CR3","doi-asserted-by":"publisher","first-page":"e648","DOI":"10.1016\/S2665-9913(23)00241-2","volume":"5","author":"F Rivellese","year":"2023","unstructured":"Rivellese F, Nerviani A, Giorli G, et al. Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials. Lancet Rheumatol. 2023;5:e648\u2013659. https:\/\/doi.org\/10.1016\/S2665-9913(23)00241-2.","journal-title":"Lancet Rheumatol"},{"key":"3618_CR4","doi-asserted-by":"publisher","unstructured":"Zhang F, Jonsson AH, Nathan A, et al. Deconstruction of rheumatoid arthritis synovium defines inflammatory subtypes. Nature. 2023;623. https:\/\/doi.org\/10.1038\/s41586-023-06708-y.:616\u2013\u200924.","DOI":"10.1038\/s41586-023-06708-y"},{"issue":"5","key":"3618_CR5","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1136\/ard-2024-225565","volume":"84","author":"F Qiu","year":"2025","unstructured":"Qiu F, Xie D, Chen H, et al. Generation of cytotoxic aptamers specifically targeting fibroblast-like synoviocytes by CSCT-SELEX for treatment of rheumatoid arthritis. Ann Rheum Dis. 2025;84(5):726\u201345. https:\/\/doi.org\/10.1136\/ard-2024-225565.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"3618_CR6","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/s41584-025-01259-0","volume":"21","author":"AE Zou","year":"2025","unstructured":"Zou AE, Kongthong S, Mueller AA, Brenner MB. Fibroblasts in immune responses, inflammatory diseases and therapeutic implications. Nat Rev Rheumatol. 2025;21(6):336\u201354. https:\/\/doi.org\/10.1038\/s41584-025-01259-0.","journal-title":"Nat Rev Rheumatol"},{"issue":"7","key":"3618_CR7","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s41584-024-01115-7","volume":"20","author":"GD Kalliolias","year":"2024","unstructured":"Kalliolias GD, Papavassiliou AG. Advancing precision rheumatology through tissue and blood profiling. Nat Rev Rheumatol. 2024;20(7):391\u201392. https:\/\/doi.org\/10.1038\/s41584-024-01115-7.","journal-title":"Nat Rev Rheumatol"},{"issue":"11","key":"3618_CR8","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/s41577-021-00540-z","volume":"21","author":"S Davidson","year":"2021","unstructured":"Davidson S, Coles M, Thomas T, et al. Fibroblasts as immune regulators in infection, inflammation and cancer. Nat Rev Immunol. 2021;21(11):704\u201317. https:\/\/doi.org\/10.1038\/s41577-021-00540-z.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"3618_CR9","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/s41467-018-02892-y","volume":"9","author":"F Mizoguchi","year":"2018","unstructured":"Mizoguchi F, Slowikowski K, Wei K, et al. Functionally distinct disease-associated fibroblast subsets in rheumatoid arthritis. Nat Commun. 2018;9(1):789. https:\/\/doi.org\/10.1038\/s41467-018-02892-y.","journal-title":"Nat Commun"},{"issue":"1","key":"3618_CR10","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13075-024-03343-4","volume":"26","author":"H Qian","year":"2024","unstructured":"Qian H, Deng C, Chen S, et al. Targeting pathogenic fibroblast-like synoviocyte subsets in rheumatoid arthritis. Arthritis Res Ther. 2024;26(1):103. https:\/\/doi.org\/10.1186\/s13075-024-03343-4.","journal-title":"Arthritis Res Ther"},{"issue":"suppl 2","key":"3618_CR11","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1136\/annrheumdis-2019-eular.3028","volume":"78","author":"R Finch","year":"2019","unstructured":"Finch R, Sostelly A, Sue-Ling K. Results of a phase 2 study of RG6125, an anti-Cadherin-11 monoclonal antibody, in rheumatoid arthritis patients with an inadequate response to anti-TNFalpha therapy. Ann Rheum Dis. 2019;78(suppl 2):189. https:\/\/doi.org\/10.1136\/annrheumdis-2019-eular.3028.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3618_CR12","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/s13075-020-02336-3","volume":"22","author":"T Takeuchi","year":"2020","unstructured":"Takeuchi T, Tanaka Y, Erdman J, et al. ASP5094, a humanized monoclonal antibody against integrin alpha- 9, did not show efficacy in patients with rheumatoid arthritis refractory to methotrexate: results from a phase 2A, randomized, double- blind, placebo-controlled trial. Arthritis Res Ther. 2020;22(1):252. https:\/\/doi.org\/10.1186\/s13075-020-02336-3.","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"3618_CR13","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/art.41555","volume":"73","author":"Y Tanaka","year":"2021","unstructured":"Tanaka Y, Takeuchi T, Yamanaka H, et al. Efficacy and safety of E6011, an Anti-Fractalkine monoclonal antibody, in patients with active rheumatoid arthritis with inadequate response to methotrexate: results of a randomized, Double-Blind, Placebo-Controlled phase II study. Arthritis Rheumatol. 2021;73(4):587\u201395. https:\/\/doi.org\/10.1002\/art.41555.","journal-title":"Arthritis Rheumatol"},{"key":"3618_CR14","doi-asserted-by":"publisher","first-page":"101350","DOI":"10.1016\/j.mam.2025.101350","volume":"102","author":"V Cesarini","year":"2025","unstructured":"Cesarini V, Appleton SL, de Franciscis V, Catalucci D. The recent blooming of therapeutic aptamers. Mol Aspects Med. 2025;102:101350. https:\/\/doi.org\/10.1016\/j.mam.2025.101350.","journal-title":"Mol Aspects Med"},{"key":"3618_CR15","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/s41590-024-01774-4","volume":"25","author":"S Rauber","year":"2024","unstructured":"Rauber S, Mohammadian H, Schmidkonz C, et al. CD200+ fibroblasts form a pro-resolving mesenchymal network in arthritis. Nat Immunol. 2024;25:682\u201392. https:\/\/doi.org\/10.1038\/s41590-024-01774-4.","journal-title":"Nat Immunol"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03618-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-025-03618-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03618-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T13:54:54Z","timestamp":1752501294000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-025-03618-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,14]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3618"],"URL":"https:\/\/doi.org\/10.1186\/s13075-025-03618-4","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,14]]},"assertion":[{"value":"22 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors agreed to the publication of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"148"}}